Actively Recruiting
Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery
Led by Nanchong Central Hospital · Updated on 2026-04-02
110
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the safety and efficacy of postoperative Pre-emptive EVT (PEVT) in reducing the incidence of anastomotic leaks within 30 days after surgery in patients with colorectal cancer. Compare the differences between the PEVT group and the control group in terms of operation time, length of hospital stay, and total medical costs. Analyze the incidence of other postoperative complications in the two groups, such as wound infection, abdominal abscess, and intestinal obstruction. Assess the impact of PEVT on postoperative recovery indicators, including time to first flatus, time to first defecation, and time to ambulation. Observe the occurrence of PEVT-related adverse events, such as device displacement, bleeding, and infection.
CONDITIONS
Official Title
Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with colorectal cancer and planned for radical surgery such as right hemicolectomy, left hemicolectomy, or anterior resection of the rectum
- Age between 18 and 85 years
- American Society of Anesthesiologists (ASA) classification I to III
- Planned single-stage anastomosis meeting criteria
- Able to understand and sign informed consent and comply with follow-up
You will not qualify if you...
- Existing anastomotic leakage or severe intra-abdominal infection before surgery
- Severe cardiovascular or cerebrovascular diseases like recent myocardial infarction or acute stroke
- Severe liver dysfunction (Child-Pugh class C) or kidney dysfunction (creatinine clearance less than 30 ml/min)
- Blood clotting disorders or anticoagulant therapy that cannot be changed
- History of abdominal radiotherapy or multiple abdominal surgeries causing severe adhesions
- Other malignant tumors with ongoing radiotherapy or chemotherapy
- Psychiatric illness or cognitive problems preventing study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanchong Central Hospital
Nanchong, Sichuan, China, 637000
Actively Recruiting
Research Team
Y
Yunhong Tian Tian, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here